FAQ: Nutriband Inc.'s AVERSA™ Technology and FDA Submission Progress

What is Nutriband Inc. and what is its primary focus?

Nutriband Inc. (NASDAQ: NTRB) is a company primarily engaged in developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating its AVERSA™ technology.

What is AVERSA™ technology and how does it work?

AVERSA™ is an abuse-deterrent technology that incorporates aversive agents into transdermal patches to prevent misuse, abuse, diversion, and accidental exposure of drugs with abuse potential, specifically designed for fentanyl patches.

Why is Nutriband’s technology significant in the pharmaceutical industry?

The technology addresses the critical need to prevent fentanyl misuse and accidental exposure, which is a major public health concern, while creating a novel approach to drug safety in transdermal delivery systems.

How is Nutriband protecting its intellectual property globally?

Nutriband has built a global IP protection strategy by securing patents across the United States, Europe, Asia, and Australia to protect its AVERSA™ technology and maintain competitive advantage.

What manufacturing progress has Nutriband made for commercialization?

The company has scaled up commercialization manufacturing in collaboration with Kindeva, positioning itself for FDA submission and potential market launch of its AVERSA™ Fentanyl product.

What is the current status of FDA approval for AVERSA™ Fentanyl?

Nutriband is poised for submission to the FDA and is focused on finalizing its development pathway to FDA approval, which would unlock major revenue opportunities upon successful commercialization.

Where can investors find more information about Nutriband Inc.?

Investors can visit the company’s website at www.Nutriband.com or access the latest news and updates in the company’s newsroom at https://ibn.fm/NTRB for comprehensive information.

What are the potential benefits for shareholders if FDA approval is obtained?

Successful FDA approval and commercialization would unlock major revenue opportunities for Nutriband, creating significant value for shareholders through market entry of its innovative abuse-deterrent technology.